Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + tuvonralimab with or without albumin-bound paclitaxel in PD-(L)1-resistant advanced cervical cancer
ChiCTR2600131941Phase 2Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of iparomlimab, tuvonralimab and paclitaxel in Cervical Cancer (CC) (3 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoint: Disease relief rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabpaclitaxel
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600131941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131941.